@joeycav11 : hey neighbor from the North.....
Yes, that is what I am saying after analyzing Slide 14 of the Phase 2 results presentation from August 09, 2016. You might want to go back and take a look.
I put the Humira and Baricitinimib numbers together based on that.
So yes, yes and YES to your question.
PS: I don't think many people are grasping the enormity of the RA trial results nor the Cures Act provision for accelerated approval (conditional approval without Phase 3 completion).
Two GREAT takeaways, page-8
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |